Advances in prevention and treatment of chemotherapy-induced gastrointestinal mucositis with proton pump inhibitors

World Chinese Journal of Digestology

Volumn 22, Issue 5, 2014, Pages 642-647

  Xie, Yi Lang ^a   Huang, Qi Chun ^a  

^a GUANGXI MEDICAL UNIVERSITY   (China)

Author keywords

Chemotherapyinduced; Gastrointestinal mucositis; Prevention treatment; Proton pump inhibitors

Indexed keywords

OMEPRAZOLE; PROTON PUMP INHIBITOR;

CHEMOTHERAPY; EPIGASTRIC PAIN; GASTROINTESTINAL MUCOSITIS; MUCOSA INFLAMMATION; PREVENTION AND CONTROL; REVIEW;

EID: 84893017507     PISSN: 10093079     EISSN: None     Source Type: Journal    
DOI: 10.11569/wcjd.v22.i5.642     Document Type: Review

References (49)

1. Heidelbaugh JJ, Metz DC, Yang YX. Proton pump inhibitors: are they overutilised in clinical practice and do they pose significant risk? Int J Clin Pract 2012; 66: 582-591 [PMID: 22607510 DOI: 10.1111/ j.1742-1241.2012.02921.x]
2. Sartori S, Trevisani L, Nielsen I, Tassinari D, Abbasciano V. Misoprostol and omeprazole in the prevention of chemotherapy-induced acute gastroduodenal mucosal injury. A randomized, placebocontrolled pilot study. Cancer 1996; 78: 1477-1482 [PMID: 8839554]
3. Sartori S, Trevisani L, Nielsen I, Tassinari D, Panzini I, Abbasciano V. Randomized trial of omeprazole or ranitidine versus placebo in the prevention of chemotherapy-induced gastroduodenal injury. J Clin Oncol 2000; 18: 463-467 [PMID: 10653861]
4. Rubenstein EB, Peterson DE, Schubert M, Keefe D, McGuire D, Epstein J, Elting LS, Fox PC, Cooksley C, Sonis ST. Clinical practice guidelines for the prevention and treatment of cancer therapy-induced oral and gastrointestinal mucositis. Cancer 2004; 100: 2026-2046 [PMID: 15108223 DOI: 10.1002/ cncr.20163]
5. Sultani M, Stringer AM, Bowen JM, Gibson RJ. Anti-inflammatory cytokines: important immunoregulatory factors contributing to chemotherapyinduced gastrointestinal mucositis. Chemother Res Pract 2012; 2012: 490804 [PMID: 22973511 DOI: 10.1155/2012/490804]
6. Sonis ST. Pathobiology of oral mucositis: novel insights and opportunities. J Support Oncol 2007; 5: 3-11 [PMID: 18046993]
7. Lawrence T. The nuclear factor NF-kappaB pathway in inflammation. Cold Spring Harb Perspect Biol 2009; 1: a001651 [PMID: 20457564 DOI: 10.1101/ cshperspect.a001651]
8. Logan RM, Stringer AM, Bowen JM, Gibson RJ, Sonis ST, Keefe DM. Is the pathobiology of chemotherapy-induced alimentary tract mucositis influenced by the type of mucotoxic drug administered? Cancer Chemother Pharmacol 2009; 63: 239-251 [PMID: 18351341 DOI: 10.1007/s00280-008-0732-8]
9. Perfetto B, Donnarumma G, Criscuolo D, Paoletti I, Grimaldi E, Tufano MA, Baroni A. Bacterial components induce cytokine and intercellular adhesion molecules-1 and activate transcription factors in dermal fibroblasts. Res Microbiol 2003; 154: 337-344 [PMID: 12837509 DOI: 10.1016/ s0923-2508(03)00084-6]
10. Sonis ST, O'Donnell KE, Popat R, Bragdon C, Phelan S, Cocks D, Epstein JB. The relationship between mucosal cyclooxygenase-2 (COX-2) expression and experimental radiation-induced mucositis. Oral Oncol 2004; 40: 170-176 [PMID: 14693241]
11. Stringer AM, Gibson RJ, Bowen JM, Keefe DM. Chemotherapy-induced modifications to gastrointestinal microflora: evidence and implications of change. Curr Drug Metab 2009; 10: 79-83 [PMID: 19149515]
12. Tarnawski AS, Ahluwalia A, Jones MK. The mechanisms of gastric mucosal injury: focus on microvascular endothelium as a key target. Curr Med Chem 2012; 19: 4-15 [PMID: 22300071]
13. Tulassay Z, Herszényi L. Gastric mucosal defense and cytoprotection. Best Pract Res Clin Gastroenterol 2010; 24: 99-108 [PMID: 20227024 DOI: 10.1016/ j.bpg.2010.02.006]
14. Ricciotti E, FitzGerald GA. Prostaglandins and inflammation. Arterioscler Thromb Vasc Biol 2011; 31: 986-1000 [PMID: 21508345 DOI: 10.1161/atvbaha. 110.207449]
15. Tsuji S, Sun WH, Tsujii M, Kawai N, Kimura A, Kakiuchi Y, Yasumaru S, Komori M, Murata H, Sasaki Y, Kawano S, Hori M. Lansoprazole induces mucosal protection through gastrin receptor-dependent up-regulation of cyclooxygenase-2 in rats. J Pharmacol Exp Ther 2002; 303: 1301-1308 [PMID: 12438555 DOI: 10.1124/jpet.102.035204]
16. Kobayashi S, Nakajima N, Ito Y, Moriyama M. Effects of lansoprazole on the expression of VEGF and cellular proliferation in a rat model of acetic acid-induced gastric ulcer. J Gastroenterol 2010; 45: 846-858 [PMID: 20333532 DOI: 10.1007/s00535-010-0224-6]
17. Al-Dasooqi N, Gibson RJ, Bowen JM, Logan RM, Stringer AM, Keefe DM. Matrix metalloproteinases are possible mediators for the development of alimentary tract mucositis in the dark agouti rat. Exp Biol Med (Maywood) 2010; 235: 1244-1256 [PMID: 20682600 DOI: 10.1258/ebm.2010.010082]
18. Lapenna D, de Gioia S, Ciofani G, Festi D, Cuccurullo F. Antioxidant properties of omeprazole. FEBS Lett 1996; 382: 189-192 [PMID: 8612750]
19. Blandizzi C, Fornai M, Colucci R, Natale G, Lubrano V, Vassalle C, Antonioli L, Lazzeri G, Del Tacca M. Lansoprazole prevents experimental gastric injury induced by non-steroidal anti-inflammatory drugs through a reduction of mucosal oxidative damage. World J Gastroenterol 2005; 11: 4052-4060 [PMID: 15996031]
20. Simon WA, Sturm E, Hartmann HJ, Weser U. Hydroxyl radical scavenging reactivity of proton pump inhibitors. Biochem Pharmacol 2006; 71: 1337-1341 [PMID: 16494850 DOI: 10.1016/j.bcp.2006.01.009]
21. Biswas K, Bandyopadhyay U, Chattopadhyay I, Varadaraj A, Ali E, Banerjee RK. A novel antioxidant and antiapoptotic role of omeprazole to block gastric ulcer through scavenging of hydroxyl radical. J Biol Chem 2003; 278: 10993-11001 [PMID: 12529378 DOI: 10.1074/jbc.M210328200]
22. Pastoris O, Verri M, Boschi F, Kastsiuchenka O, Balestra B, Pace F, Tonini M, Natale G. Effects of esomeprazole on glutathione levels and mitochondrial oxidative phosphorylation in the gastric mucosa of rats treated with indomethacin. Naunyn Schmiedebergs Arch Pharmacol 2008; 378: 421-429 [PMID: 18545984 DOI: 10.1007/s00210-008-0314-7]
23. Koch TR, Petro A, Darrabie M, Opara EC. Effect of the H, K-ATPase inhibitor, esomeprazole magnesium, on gut total antioxidant capacity in mice. J Nutr Biochem 2004; 15: 522-526 [PMID: 15350983 DOI: 10.1016/j.jnutbio.2004.03.003]
24. Burger D, Xiang F, Hammoud L, Lu X, Feng Q. Role of heme oxygenase-1 in the cardioprotective effects of erythropoietin during myocardial ischemia and reperfusion. Am J Physiol Heart Circ Physiol 2009; 296: H84-H93 [PMID: 18996987 DOI: 10.1152/ajpheart. 00372.2008]
25. Coëffier M, Le Pessot F, Leplingard A, Marion R, Lerebours E, Ducrotté P, Déchelotte P. Acute enteral glutamine infusion enhances heme oxygenase-1 expression in human duodenal mucosa. J Nutr 2002; 132: 2570-2573 [PMID: 12221210]
26. Barton SG, Rampton DS, Winrow VR, Domizio P, Feakins RM. Expression of heat shock protein 32 (hemoxygenase-1) in the normal and inflamed human stomach and colon: an immunohistochemical study. Cell Stress Chaperones 2003; 8: 329-334 [PMID: 15115285]
27. Vijayan V, Mueller S, Baumgart-Vogt E, Immenschuh S. Heme oxygenase-1 as a therapeutic target in inflammatory disorders of the gastrointestinal tract. World J Gastroenterol 2010; 16: 3112-3119 [PMID: 20593496]
28. Guo X, Shin VY, Cho CH. Modulation of heme oxygenase in tissue injury and its implication in protection against gastrointestinal diseases. Life Sci 2001; 69: 3113-3119 [PMID: 11758836]
29. Umeda K, Takahashi T, Inoue K, Shimizu H, Maeda S, Morimatsu H, Omori E, Akagi R, Katayama H, Morita K. Prevention of hemorrhagic shock-induced intestinal tissue injury by glutamine via heme oxygenase-1 induction. Shock 2009; 31: 40-49 [PMID: 18497709 DOI: 10.1097/SHK.0b013e318177823a]
30. Chang AY, Chan JY, Cheng HL, Tsai CY, Chan SH. Hypoxia-inducible factor 1/heme oxygenase 1 cascade as upstream signals in the prolife role of heat shock protein 70 at rostral ventrolateral medulla during experimental brain stem death. Shock 2009; 32: 651-658 [PMID: 19333137 DOI: 10.1097/ SHK.0b013e3181a71027]
31. Cooper KL, Liu KJ, Hudson LG. Enhanced ROS production and redox signaling with combined arsenite and UVA exposure: contribution of NADPH oxidase. Free Radic Biol Med 2009; 47: 381-388 [PMID: 19414066 DOI: 10.1016/j.freeradbiomed.2009.04.034]
32. Takagi T, Naito Y, Yoshikawa T. The expression of heme oxygenase-1 induced by lansoprazole. J Clin Biochem Nutr 2009; 45: 9-13 [PMID: 19590701 DOI: 10.3164/jcbnSR09-28]
33. Takagi T, Naito Y, Okada H, Ishii T, Mizushima K, Akagiri S, Adachi S, Handa O, Kokura S, Ichikawa H, Itoh K, Yamamoto M, Matsui H, Yoshikawa T. Lansoprazole, a proton pump inhibitor, mediates anti-inflammatory effect in gastric mucosal cells through the induction of heme oxygenase-1 via activation of NF-E2-related factor 2 and oxidation of kelch-like ECH-associating protein 1. J Pharmacol Exp Ther 2009; 331: 255-264 [PMID: 19628634 DOI: 10.1124/jpet.109.152702]
34. Smith WB, Gamble JR, Clark-Lewis I, Vadas MA. Interleukin-8 induces neutrophil transendothelial migration. Immunology 1991; 72: 65-72 [PMID: 1997402]
35. Handa O, Yoshida N, Fujita N, Tanaka Y, Ueda M, Takagi T, Kokura S, Naito Y, Okanoue T, Yoshikawa T. Molecular mechanisms involved in antiinflammatory effects of proton pump inhibitors. Inflamm Res 2006; 55: 476-480 [PMID: 17122965 DOI: 10.1007/s00011-006-6056-4]
36. Kuroda M, Yoshida N, Ichikawa H, Takagi T, Okuda T, Naito Y, Okanoue T, Yoshikawa T. Lansoprazole, a proton pump inhibitor, reduces the severity of indomethacin-induced rat enteritis. Int J Mol Med 2006; 17: 89-93 [PMID: 16328016]
37. Sasaki T, Yamaya M, Yasuda H, Inoue D, Yamada M, Kubo H, Nishimura H, Sasaki H. The proton pump inhibitor lansoprazole inhibits rhinovirus infection in cultured human tracheal epithelial cells. Eur J Pharmacol 2005; 509: 201-210 [PMID: 15733557 DOI: 10.1016/j.ejphar.2004.12.042]
38. Shin JM, Kim N. Pharmacokinetics and pharmacodynamics of the proton pump inhibitors. J Neurogastroenterol Motil 2013; 19: 25-35 [PMID: 23350044 DOI: 10.5056/jnm.2013.19.1.25]
39. Ward RM, Kearns GL. Proton pump inhibitors in pediatrics: mechanism of action, pharmacokinetics, pharmacogenetics, and pharmacodynamics. Paediatr Drugs 2013; 15: 119-131 [PMID: 23512128 DOI: 10.1007/s40272-013-0012-x]
40. Morita H, Mochiki E, Takahashi N, Kawamura K, Watanabe A, Sutou T, Ogawa A, Yanai M, Ogata K, Fujii T, Ohno T, Tsutsumi S, Asao T, Kuwano H. Effects of 5-HT2B, 5-HT3 and 5-HT4 receptor antagonists on gastrointestinal motor activity in dogs. World J Gastroenterol 2013; 19: 6604-6612 [PMID: 24151388 DOI: 10.3748/wjg.v19.i39.6604]
41. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: AntiemesisV. 1.2012. Available from: URL: http: //www. nccn.org/professionals/physician_gls/f_guidelines. asp
42. Shields HM, Recht A, Wang HH. Exposure to both radiation and chemotherapy increases the risk of Barrett's and multilayered epithelium. Dig Dis Sci 2009; 54: 2143-2149 [PMID: 19093207 DOI: 10.1007/ s10620-008-0619-x]
43. Tutuian R. Adverse effects of drugs on the esophagus. Best Pract Res Clin Gastroenterol 2010; 24: 91-97 [PMID: 20227023 DOI: 10.1016/j.bpg.2010.02.005]
44. Uwagawa T, Misawa T, Iida T, Sakamoto T, Gocho T, Wakiyama S, Hirohara S, Yanaga K. Protonpump inhibitor as palliative care for chemotherapyinduced gastroesophageal reflux disease in pancreatic cancer patients. J Palliat Med 2010; 13: 815-818 [PMID: 20636150 DOI: 10.1089/jpm.2009.0404]
45. Brunner G, Athmann C, Schneider A. Long-term, open-label trial: safety and efficacy of continuous maintenance treatment with pantoprazole for up to 15 years in severe acid-peptic disease. Aliment Pharmacol Ther 2012; 36: 37-47 [PMID: 22531114 DOI: 10.1111/j.1365-2036.2012.05106.x]
46. Giuliano C, Wilhelm SM, Kale-Pradhan PB. Are proton pump inhibitors associated with the development of community-acquired pneumonia? A meta-analysis. Expert Rev Clin Pharmacol 2012; 5: 337-344 [PMID: 22697595 DOI: 10.1586/ecp.12.20]
47. Yu EW, Bauer SR, Bain PA, Bauer DC. Proton pump inhibitors and risk of fractures: a metaanalysis of 11 international studies. Am J Med 2011; 124: 519-526 [PMID: 21605729 DOI: 10.1016/ j.amjmed.2011.01.007]
48. Maeda Y, Kojima N, Araki Y, Uno T, Nishigaki K, Inaba N. Does a proton pump inhibitor cause hypokalemia? Intern Med 2011; 50: 1045-1050 [PMID: 21532230]
49. Sugimoto M, Furuta T. Efficacy of esomeprazole in treating acid-related diseases in Japanese populations. Clin Exp Gastroenterol 2012; 5: 49-59 [PMID: 22649281 DOI: 10.2147/ceg.s23926]